Aotearoa Clinical Trials

Annual Report 2026

Bringing global clinical research closer to home



FY26
1 July 2025 - 30 June 2026

Contents

About us 1

Foreword from the Chair 2

CEO Report 3

Board of Trustees 4

Senior management 6

Research Physicians 8

Advancing health through clinical research 9

General performance dashboard 10

Clinical performance dashboard 11

Why we do what we do 12

How we benefit the community 13

Highlights FY26 14

Trust outcomes 18

Celebrating Research 2025 19

Participant story: a world-class experience 20

The person behind the participant 21

Staff Awards 22

Grant-funded trials and highlights 23

Commercial trials 26

Commercial trials - feasibilities 27

Commercial trials by the numbers 28

Areas of research - activity by department in FY26 29

Reserve balances 33

Publications 34

About us

Aotearoa Clinical Trials Trust (ACTT) is Aotearoa New Zealand's largest clinical trials network based at public hospitals, connecting researchers, clinicians, sponsors and participants through a nationally coordinated model.

For more than 25 years, we have brought world-class clinical research closer to communities in Aotearoa New Zealand, creating opportunities for people to access innovative medicines, therapies and advances in healthcare.

Our hospital-based clinical trial units supported by specialist investigators enable reliable recruitment and strong participant engagement. We operate fully integrated research units at Middlemore Hospital in South Auckland and Whangārei Hospital in Te Tai Tokerau - Northland, collaborating with more than 28 hospital departments across a wide range of therapeutic areas - from oncology, cardiology, and haematology to diabetes, paediatrics, respiratory health, renal medicine, and surgery.

Our purpose is to improve the health of all New Zealanders through equitable access to world-class clinical trials, and to ensure that our communities are represented in the development of safe and effective therapies. Clinical research is a powerful way to improve health outcomes for individuals, whānau and communities today, while we shape the healthcare of tomorrow.

As an independent charitable trust, we deliver both commercial and grant-funded research in partnership with Te Whatu Ora. Any surplus generated is reinvested into growing clinical research expertise and capacity, strengthening hospital research programmes, supporting Research Fellows, nurses and training opportunities, and enabling investigator-led studies that advance healthcare for future generations.

Our multidisciplinary team of research nurses, coordinators, pharmacists, regulatory specialists, quality managers and clinicians deliver high-quality, efficient trials to the highest scientific and operational standards. ACTT holds a gold international accreditation from IAOCR (https://iaocr.com/en) for managing sites of clinical excellence, reflecting our commitment to quality, compliance and continual improvement.

We are proud of our strong community partnerships, particularly with Māori, Pacific and Asian communities who have historically faced barriers to healthcare and clinical research participation.

Every trial contributes to better treatment options, stronger health systems and improved outcomes for future generations, while creating opportunities for people across our communities to access cutting-edge medicines, therapies and healthcare technologies.

ACTT holds both GCSA certification and workforce quality accreditation, and was the first research organisation in Aotearoa New Zealand to achieve these standards.

Foreword from the Chair

Building on strong foundations



Greg Batkin
Chair

FY26 has been a significant year for ACTT, reflecting the continued growth, maturity and impact of our organisation. As Chair, I have had the privilege of witnessing the dedication of our investigators, research teams, staff, partners and participants who make our work possible and who continue to strengthen clinical research across Aotearoa New Zealand.

Clinical research plays a critical role in improving health outcomes. It provides access to innovative treatments including for those for whom standard of care treatments have failed, contributes to medical knowledge, and helps ensure healthcare decisions are guided by evidence.

ACTT's purpose remains clear: to increase access to high-quality clinical research and ensure more communities can benefit from the opportunities and outcomes that research enables. The achievement of a National Deed with Health New Zealand is another step in achieving ACTT's objectives.

During the year, ACTT continued to demonstrate strong organisational performance. Research activity expanded across both commercial and grant-funded portfolios, our regional and community-based research capability continued to grow, and we strengthened partnerships that position ACTT for continued success in an increasingly competitive global research environment.

The Board was particularly pleased to see continued recognition of ACTT's commitment to quality through the achievement of Gold-level Workforce Process Quality Certification and a third consecutive year of international accreditation. These achievements, along with frequent sponsor and regulatory authority audits, provide independent assurance that ACTT is delivering research to internationally recognised standards and reflects the professionalism and dedication of the people who work across our network.

Investment in capability also remained a priority throughout the year. ACTT continued to reinvest in research infrastructure, workforce development, education and training, ensuring our hospitals and research teams are well positioned to participate in increasingly complex clinical research. As a charitable trust, this commitment to reinvestment remains central to our purpose and enables ongoing growth in research capability for the benefit of our communities.

The Board also recognises the importance of equitable access to clinical research. We are encouraged by the continued growth of regional research activity, particularly in Whangārei, where ongoing investment is helping create new opportunities for Northland communities to participate in clinical trials closer to home. Expanding access to research remains a key priority for ACTT and aligns closely with our purpose.

Looking ahead, the opportunities for clinical research in Aotearoa New Zealand continue to grow. Advances in early-phase research, emerging therapies, investigator-led research and national collaboration are creating exciting possibilities for patients, clinicians and researchers alike. ACTT is well positioned to play an important role in this future through its commitment to quality, partnership, innovation and long-term capability building.

On behalf of the Board, I would like to thank our participants, investigators, research teams, partners, sponsors and supporters for their ongoing commitment to clinical research. I would also like to acknowledge Chief Executive Officer Dr Edward Watson and the ACTT leadership team for their continued leadership and dedication throughout the year.

The board itself has been busy, and welcomed Dr Vanessa Thornton and Morris Pita as new Trustees. During the year it also completed a number of tasks, reviewing its governance procedures in accordance with the requirements of the Charities Amendment Act.

Together, we are helping build a stronger clinical research ecosystem for Aotearoa New Zealand and creating opportunities to improve health outcomes for current and future generations.

CEO report

Building the foundations for a national clinical trials network



Dr Edward Watson
Chief Executive Officer

FY26 has been a year of significant progress for ACTT, marked by growth in research activity, continued investment in capability, and expansion of opportunities for patients to participate in clinical research. While we are proud of the many achievements across our network, one milestone stands above all others in its potential to shape the future of clinical research in Aotearoa New Zealand: the completion of the Health New Zealand National Deed.

For many years, clinical trial delivery across Aotearoa New Zealand has been influenced by differences in contracting processes, site arrangements, and local approval pathways. While high-quality research has continued to flourish, these variations have often created barriers to scaling research activity and ensuring equitable access to clinical trial opportunities across the country.

The completion of the National Deed represents an important step towards a more coordinated national approach. By establishing a consistent framework for engagement between sponsors, research organisations, and Health New Zealand sites, the Deed creates opportunities to simplify study start-up processes, increase efficiency, and strengthen Aotearoa New Zealand's attractiveness as a destination for clinical research.

Most importantly, this milestone has the potential to improve access to clinical trials for patients and whānau, regardless of where they live. Research participation should not be limited by geography. As a nationally connected organisation with a strong presence in both metropolitan and regional communities, ACTT sees significant opportunity to support the expansion of research across Aotearoa New Zealand and ensure more people have access to innovative treatments and research opportunities closer to home.

The National Deed also aligns closely with ACTT's long-term vision of creating a more connected and sustainable clinical research ecosystem. By reducing barriers to participation and enabling greater collaboration across the health system, it helps establish the foundations required for future growth in both commercial and investigator-led research.

While strategic progress has been a defining feature of FY26, it has been matched by strong operational performance. During the year, ACTT supported 52 enrolling studies, managed more than 150 commercial and grant-funded trials, worked with over 50 global sponsors, and continued to invest in the people, infrastructure and systems that underpin high-quality research delivery. These achievements reflect the dedication of our investigators, research nurses, coordinators, pharmacists, support staff, governance team, and partners across the health sector. This year we achieved Gold status for managing clinical trial sites of clinical excellence from the International Accrediting Organisation for Clinical Research (IAOCR).

As we look ahead, the opportunities for clinical research in Aotearoa New Zealand have never been greater. Demand for access to innovative therapies continues to grow, investment in research capability is increasing, and the establishment of a national framework through the Health New Zealand National Deed provides a platform for future expansion.

I would like to thank our participants, investigators, research teams, partners, sponsors, and supporters for their contribution throughout the year. Also thanks to the ACTT Board for their continuing support and guidance as we expand what we can offer to hospitals and participants. Together, we are helping ensure that more New Zealanders can benefit from clinical research, while contributing to the evidence and innovations that will improve health outcomes for generations to come.

Board of Trustees FY26



Greg Batkin (Chair)

Greg brings to the Board a range of commercial, financial and strategic skills and experience. He has worked across a variety of business sectors, including automotive, energy, agriculture and life sciences, and has previously held Chief Investment Officer and Chief Executive roles. In addition to serving as Chair of ACTT, Greg is Deputy Chair of Safer Sleep, an anaesthetic software company, a director of a large private business based in South Auckland, and a Trustee of Cancer Research Trust New Zealand.



Sanjoy Nand

Sanjoy is currently the Chief of Allied Health Scientific and Technical Office at Counties Manukau, Health New Zealand and serves on the Senior Leadership Team for the Northern Region. He is an experienced health sector leader with a background in clinical and operational leadership roles within the Aotearoa New Zealand public healthcare system. A qualified pharmacist, Sanjoy also has extensive knowledge and experience in the pharmaceutical sector. He is a Chartered Member of the Institute of Directors.



Kevin Wightman

Kevin has worked in Clinical Research in Australia and Aotearoa New Zealand for over 25 years. He is passionate about improving the delivery of clinical trials to better meet patients' needs, with more than 30 years' experience in leading Pharma, CRO, site and patient-centric solution providers across Asia Pacific, the US and Europe. Kevin is a member of the Australian Institute of Company Directors (AICD) and brings unique perspectives, stakeholder networks and insights from both industry and site angles, drawing on his Board and Non-executive Director experience with industry associations and not-for-profit organisations.



Whetumarama (Marama) Parore

Ngāti Whātua, Ngāpuhi, Ngāti Kahu and Ngāti Pōneke

Marama is an experienced Māori leader with extensive expertise across health, disability, community development, governance and public sector transformation in Aotearoa New Zealand. She has held senior executive and advisory roles with organisations including Whaikaha, Te Aka Whai Ora, PHARMAC, Prison Fellowship NZ, HealthCare NZ, TAS and Te Rau Matatini. Marama is recognised for advancing whānau voice, equity and Te Tiriti o Waitangi in strategy, policy and service design, bringing significant experience in governance, system improvement and kaupapa Māori leadership to the ACTT Board.



Michael James

Michael's international career has spanned commercial and financial leadership roles across high-tech and innovation industries in both the public and private sectors. He is an experienced director in the infrastructure and innovation sectors and brings a wealth of commercial, financial and strategic expertise to the Board.



Morris Pita MNZM

Ngātiwai me Ngāti Hine

Morris is an experienced company director, entrepreneur and executive with more than 30 years' experience in governance, strategy and commercial leadership across the health, technology, energy, agribusiness and infrastructure sectors. He is the founder and Chief Executive of Tai Pari Mōhio Ltd, developer of the award-winning Emergency Q digital health platform. Morris has served on the Boards of Waitematā and Auckland District Health Boards and was a Trustee of Eden Park, where he chaired the Finance and Audit Committee. He currently serves as Co-chair of the Whangaroa Ngaiotonga Trust and Chair of Manawaroa Limited, bringing extensive governance and health sector expertise to the ACTT Board.



Dr Vanessa Thornton

Vanessa is an experienced health sector leader with extensive expertise in clinical operations, healthcare management and service improvement. An Emergency Medicine specialist by training, she has held senior clinical and operational leadership roles within Health New Zealand Counties Manukau. Vanessa has contributed to regional and national initiatives focused on emergency care performance, patient flow and health system improvement. She is currently Group Director of Operations, Hospital and Specialist Services at Health New Zealand Counties Manukau and brings significant clinical, operational and strategic leadership experience to the ACTT Board.

Senior management



Karen Carter
Director -
Clinical Operations

Operations team

The Operations team led by Karen Carter plays a critical role in delivering high-quality, participant-centred, clinical trials across ACTT's sites. This multidisciplinary team collaborates closely with investigators, hospital departments, sponsors, CROs, regulatory bodies, and third-party providers to ensure the seamless coordination of nursing, phlebotomy, laboratory, eClinical, and pharmacy services, enabling studies to be delivered safely, efficiently and to the highest standards of quality and compliance.

People, safety, and quality are at the heart of our work. Over the past year, key milestones have included the successful growth and integration of the Whangārei team, and the promotion of several team members - reflecting ACTT's commitment to strengthening clinical research capability and developing future research leaders within Aotearoa New Zealand's health system.



Kate Msiska
Director -
Commercial Trials

Business team

The Business team led by Kate Msiska creates the foundations that enable new clinical research opportunities to be delivered across ACTT's network.

This includes business development, feasibility assessments, budget negotiations, contract management, regulatory processes, set-up logistics, and sponsor and investigator relationship management, to bring innovative new studies to Aotearoa New Zealand communities through ACTT's research network.

With an expanding team, including a Regulatory Lead and Start-up Specialists, we focus on building strong foundations for every trial, ensuring compliance, efficiency, and trusted collaboration with commercial partners, while supporting timely study activation and expanding access to clinical research opportunities.

Our work enables ACTT to expand access to innovative clinical trials that benefit patients and support the health system.



Nicola Jackson, PhD
Director – Grant Research

Grants team

The Grants team, led by Nicola Jackson, PhD, enables high-impact, non-commercial research by supporting clinicians through every stage of grant-funded, collaborative and investigator-led research. We work alongside researchers to secure funding, manage trials, and share results, helping to bring public-good research to life and strengthening opportunities for investigator-led research across Aotearoa New Zealand.

Our work is underpinned by a commitment to innovation, collaboration, and equity of access. By reinvesting commercial trial revenue into non-commercial studies, ACTT strengthens research capability, supports investigator-led innovation and creates long-term benefits for patients, communities and the wider health system.



Emani Setefano
Director - Finance

Finance team

The Finance team led by Emani Setefano provides essential financial management and oversight to ensure the stability and sustainability of ACTT's operations. We are responsible for budgeting, reporting, and compliance, ensuring resources are managed responsibly and aligned to ACTT's purpose and long-term growth.

By adopting digital tools and improving processes, we help streamline operations and enable clinical teams to focus on delivering high-quality research. The team's work is underpinned by integrity, accuracy, and a commitment to supporting ACTT's long-term success, including our ability to reinvest in future clinical research capability and capacity across the public health system.



Dr Renate Koops
Clinical Director and
Research Physician

Research Physicians team

"Clinical research is vital for advancing our knowledge about safety and effectiveness of new treatments, ultimately improving patient care. Without clinical research there is no future medicine." - Dr Renate Koops

ACTT partners with hospital-based Research Physicians who bring extensive expertise from their work in affiliated hospitals and community general practices.

These physicians play a vital role in supporting departments interested in research but lacking the time or resources to conduct studies independently. Collaborating closely with the clinical trial operations team, including trial coordinators and nurses, they help facilitate high-quality clinical trials across a wide range of medical specialties. This collaboration expands research opportunities for patients throughout Aotearoa New Zealand. In addition to providing support, ACTT Research Physicians also serve as Principal Investigators, taking responsibility for the delivery and oversight of clinical trials that are of research interest to them.

Their involvement strengthens the connection between research and clinical care, ensuring more patients can access innovative treatments and benefit from research-driven healthcare.

Research Physicians



Dr Kate Bradley

"I am excited to be part of a team working with innovative therapies and helping to translate research into meaningful improvements in health outcomes."



Dr Rita Kettoola

"It's a real privilege to work alongside trial participants in innovative research. There's something truly exciting about seeing new treatments years before they reach the wider community, and knowing that our work helps shape the evidence that guides their future use."



Dr May Lim

"I am very excited to be part of groundbreaking medical advancements that improve patient outcomes and help shape the future of healthcare. I appreciate that clinical research allows me to maintain a strong element of patient contact when assessing trial participants, while also engaging in important non-patient-facing work."



Dr Ian Rosen

"My main motivation for involvement in clinical research is being at the forefront of new medications that are in development for diseases such as diabetes and lipid disorders."



Dr Aritra Ray

"What motivates me to work in clinical research is the team spirit and the generosity of volunteers who give their time and health to further medical advancements."



Dr Joanna Wojciechowska

"If I can help to save even one life - then everything makes sense."

Advancing health through clinical research



ACTT improves health outcomes by making clinical research more accessible to patients, whānau and communities across Aotearoa New Zealand. Through partnerships across the health and research sectors, we help bring innovative treatments, research opportunities and clinical expertise closer to the people who can benefit from clinical research.

As an independent charitable trust, we provide the specialist infrastructure, systems and expertise needed to deliver high-quality clinical research within Aotearoa New Zealand's public health system. Our work supports the delivery of commercial, grant-funded, collaborative and investigator-initiated studies across a broad range of therapeutic areas.

Together, these studies generate new knowledge, expand access to research opportunities, build clinical research capability and help address important health priorities for Aotearoa New Zealand communities.

Commercial trials

Commercial trials partner ACTT with biopharmaceutical companies and contract research organisations from around the world to deliver Phase Ib to Phase IV clinical trials across a diverse range of therapeutic areas.

These studies provide opportunities for patients to access innovative medicines and therapies while contributing to the development of future treatments. Revenue generated through commercial research also helps build clinical research capability and capacity within Aotearoa New Zealand's public health system.

Grant-funded trials

Grant-funded trials are supported by public health organisations such as the Health Research Council, charitable foundations and other funding bodies to address priority health challenges for Aotearoa New Zealand.

These studies generate evidence that informs healthcare decisions, improves patient outcomes and creates opportunities for clinicians and researchers to investigate important healthcare questions that benefit the communities we serve.

Collaborative group trials

Collaborative group trials bring together clinicians, researchers and institutions to answer important healthcare questions and generate evidence that can improve healthcare.

By participating in national and international research networks, we help strengthen research capability, share expertise and ensure research findings are relevant to the populations and communities they are intended to benefit.

Investigator-initiated trials

Investigator-initiated trials are led by clinicians and researchers who identify important questions arising from clinical practice and community need.

These studies support innovation, develop research leadership and generate evidence that reflects Aotearoa New Zealand's unique healthcare environment. By supporting investigator-led research, ACTT helps build local research capability and create opportunities for new ideas to be translated into improved health outcomes.

General performance dashboard FY26

STAFF



ALL STAFF

Total staff including contractors who worked at ACTT during FY26

62

RESEARCH STAFF

Includes Nurses, Clinical Trial Coordinators, Phlebotomists and Pharmacists

36

TRIAL METRICS



COMMERCIAL TRIALS

Total number of commercial trials underway in FY26

98

GRANT-FUNDED TRIALS

Total number of active grant-funded/ investigator-led trials in FY26

81

NEW TRIAL ACTIVATIONS

Commercial trial protocols that activated during FY26

25

COMMERCIAL FEASIBILITIES

Total protocols received during FY26

270

COMMERCIAL PARTICIPANT METRICS



NEW TRIAL PARTICIPANTS

145

TOTAL PARTICIPANTS

Includes ongoing multi-year trials

504

Outpatient visits 3331

RESERVES AND REVENUE



RESERVES SPENT

10%

$762,868

RESERVES

$10m

GRANT REVENUES

$2.7m

TOTAL REVENUE

$13m

Clinical performance dashboard FY26

HOSPITAL ACTIVITY

ACTIVE DEPARTMENTS

Number of hospital departments we worked with in FY26

28

MMH 24
WRE 4

ACTIVE INVESTIGATORS

Number of investigators involved in commercial and grant trials in FY26

104

MMH 93
WRE 11

COMMUNITY CONTRIBUTIONS

REIMBURSEMENTS

Reimbursements to our community for taking part in clinical trials

$476,240

OUTPATIENT ACTIVITY

OUTPATIENT VISITS

Total outpatient visits during the course of trials

3331

MONEY SAVED

Estimated money saved by service outpatient visits

$1.5m



Infusion suite at Middlemore

Why we do what we do



ACTT exists to improve health outcomes by expanding access to clinical research across Aotearoa New Zealand. By reducing barriers to participation and building trust in clinical research, we help create opportunities for more people to benefit from research and contribute to the future of healthcare.

Access to healthcare and clinical research is not experienced equally across all communities. ACTT works to improve access to clinical trials, creating opportunities for people to participate in research, access innovative treatments and take an active role in their healthcare. Participation also contributes to new knowledge that can improve care and benefit future generations.

Clinical trials can provide access to innovative medicines and therapies that may not yet be available within Aotearoa New Zealand's healthcare system. In some studies, participants may receive treatments that are already widely used internationally but are not yet funded or routinely available in Aotearoa New Zealand. This creates opportunities for patients to access emerging treatment options while enabling local clinicians to gain experience in their use and contribute to the evidence that informs future healthcare decisions.

Through partnerships globally with biopharmaceutical companies, medical device organisations, healthcare providers and research networks, ACTT helps bring global research opportunities to Aotearoa New Zealand. By delivering clinical trials within the public health system, we enable more patients to participate in high-quality clinical research closer to home.

Growing clinical research in Aotearoa New Zealand creates benefits that extend beyond individual studies. It strengthens clinical research capability, develops research expertise, attracts new research opportunities and expands access to innovative treatments. Through this work, ACTT is helping build a stronger and more sustainable clinical research environment that benefits patients, whānau and communities across Aotearoa New Zealand.

How we benefit the community

Access to clinical research can change lives. It gives people the opportunity to access innovative treatments, receive highly personalised care and contribute to medical advances that may benefit future generations. In partnership with Middlemore and Whangārei Hospitals, ACTT brings world-class clinical trials to communities across Counties Manukau and Te Tai Tokerau, helping improve health outcomes while making research more accessible for those who need it most.

Expanding access to care and innovation

Clinical trials provide participants with dedicated support from experienced research nurses, coordinators and investigators, helping build trust, strengthen engagement and support informed healthcare decisions. They also provide access to innovative medicines and therapies often years before they become widely available through Aotearoa New Zealand's public health system, creating opportunities to improve quality of life while contributing to future advances in healthcare.

Improving health outcomes

Participation in clinical trials has been associated with improved health outcomes compared with standard care alone. Research at Middlemore Hospital has demonstrated significantly lower mortality rates and an 81% reduction in cardiovascular-related deaths among trial participants over a three-year period, highlighting the potential impact that research can have on long-term health outcomes.[1]

Advancing health equity

Improving equitable access to clinical research is central to our purpose. We work closely with Māori, Pacific and Asian communities who have historically experienced barriers to healthcare and clinical research participation. By embedding trials within public hospitals, reducing barriers to participation and providing practical support, including more than $476,000 in participant reimbursements during the year, we help ensure the benefits of research are shared more equitably across Aotearoa New Zealand.

Strengthening research and future healthcare

ACTT helps strengthen Aotearoa New Zealand's health ecosystem. Investigators gain early access and experience to cutting-edge treatments, collaborate with global experts, and become key opinion leaders themselves. Through community engagement, education and partnerships, we raise awareness of clinical trials, build trust in the research process and create opportunities for more people to participate in research. As an independent charitable trust, retained earnings generated through our work are reinvested into growing research capability and capacity, supporting investigators, research teams and future clinical research opportunities within the public health system. Together, these investments help strengthen research participation, capability and access, creating lasting benefits for patients, communities and future generations.



[1]Baker JR, Vandal AC, Yeoh J, Zeng I, Wong S, Ryan SN. Clinical trial participation improves outcome: A matched historical cohort study. *Clinical Trials*. 2013;10(5):735-743. doi:10.1177/1740774513496915

Highlights for FY26

ACCESS

- National Deed strengthens opportunities for clinical trials across Aotearoa New Zealand
- Peninsula Medical Centre joins the ACTT network
- Whangārei expands research opportunities in Northland

INNOVATION

- Advancing capability for advanced therapies
- Phase Ib capability expanded with overnight stay facilities
- Growing oncology research capability
- Expanded infusion capability supports clinical trial growth

IMPACT

- Growth in clinical trial activity across the network
- REPORT study launches to address diabetic kidney disease
- Strong recruitment performance across clinical trials
- Supporting investigator-led research
- Research published in leading international journals

QUALITY AND SUSTAINABILITY

- Gold-level international quality accreditation
- PPD select partnership program
- Investing in future research capability



ACTT is bringing more clinical trials to Northland, Aotearoa New Zealand



The new Whangārei oncology unit represents an important step in strengthening local access to cancer care closer to home

Access

National Deed strengthens opportunities for clinical trials across Aotearoa New Zealand

Recently ACTT and Health NZ signed a National Deed, providing a framework to support participation in nationally coordinated clinical research activities in all hospitals across the country that wish to partner with ACTT. The Deed strengthens opportunities for collaboration across the health system and supports a more connected research environment.

Whangārei expands research opportunities in Northland

Research activity continued to grow in Whangārei, including strong performance in cardiovascular research and the expansion of oncology capability. These developments increase opportunities for Northland communities to participate in clinical trials closer to home.

Peninsula Medical Centre joins the ACTT network

The addition of Peninsula Medical Centre expanded ACTT's network and strengthened our ability to deliver clinical trials in both community and hospital settings. The partnership broadens ACTT's reach in West Auckland and provides greater flexibility in how studies can be delivered.



University of Auckland Women in Science Careers evening

L-R Sophia Khan, Research Associate and Esther Ji, Study Start-up Specialist

Innovation

Advancing capability for advanced therapies

FY26 saw continued growth in ACTT's capability to support increasingly complex clinical trials, including advanced therapies. Successful recruitment into CRISPR-related research and investment in Phase Ib infrastructure demonstrate ACTT's growing capability in cutting-edge innovative clinical research.

Phase Ib capability expanded with overnight stay facilities

ACTT expanded overnight stay capability at Middlemore Hospital, enabling the delivery of more complex Phase Ib clinical trials. The facility supports studies requiring intensive monitoring and strengthens ACTT's ability to participate in early-phase research programmes.

Growing oncology research capability

ACTT continued to strengthen its oncology research programme through investment in people, infrastructure and partnerships. Growth in oncology activity expanded opportunities to deliver cancer clinical trials across the network and supports further development in this important therapeutic area.

Expanded infusion capability supports clinical trial growth

During FY26, ACTT expanded its infusion capability to support the delivery of oncology, rheumatology and other infusion-based clinical trials in both Middlemore and Whangārei Hospitals. The enhanced service increases capacity for complex study activity and supports the continued growth of specialist clinical trial programmes.



Impact

Growth in clinical trial activity across the network

ACTT continued to expand its clinical trial portfolio, with 52 actively enrolling trials and more than 150 commercial and grant-funded studies underway during FY26. This breadth of activity reflects the scale and diversity of research being delivered across the network.

REPORT study launches to address diabetic kidney disease

ACTT launched the REPORT Study, a collaborative initiative focused on reducing the progression of diabetic kidney disease. Bringing together primary care, specialist services, academic partners and Health NZ, the study reflects ACTT's commitment to research addressing significant health challenges facing Aotearoa New Zealand communities.

Strong recruitment performance across clinical trials

ACTT teams delivered strong recruitment outcomes across multiple clinical trials during FY26, with a number of studies exceeding enrolment targets. Consistent recruitment performance supported study delivery and contributed to strong outcomes across the clinical trial portfolio.

Supporting investigator-led research

More than 55 grant-funded, collaborative and investigator-led research studies were active across the ACTT network during FY26. This portfolio supports clinician-led innovation, contributes to academic research activity, and helps address questions relevant to Aotearoa New Zealand healthcare and communities.

Research published in leading international journals

ACTT investigators contributed to studies published in *The New England Journal of Medicine*, *The Lancet* and *Nature Medicine*. These publications demonstrate ACTT's contribution to research that is informing clinical practice and advancing medical knowledge internationally.



ChinaBio Shanghai – Dr Ed Watson, CEO, Karen Carter, Director Clinical Operations and Jimmy Chan, Deeplynx

Quality and Sustainability

Gold-level international quality accreditation

ACTT achieved Gold-level Workforce Process Quality Certification while maintaining International Accrediting Organisation for Clinical Research (IAOCR) accreditation across both Middlemore and Whangārei Hospitals. These achievements recognise the strength of ACTT's quality systems, workforce capability and commitment to internationally recognised standards.

PPD Select Partnership Program

ACTT was selected to participate in the PPD Select Partnership Program, recognising the strength of its relationship with the PPD clinical research business of Thermo Fisher Scientific. The partnership supports participation in globally significant clinical research programmes and strengthens ACTT's international connections.

Investing in future research capability

ACTT invested more than $760,000 in research capability across Middlemore and Whangārei Hospitals. Funding supported research nurses, coordinators, fellows, training, conference participation, publications and infrastructure, helping build the workforce and capability required to support future growth in clinical trials.



ARCS Conference

L-R Kate Msiska, Director - Commercial Research and Tanya Poppe, Regulatory Lead

Trust outcomes


ACTT's charitable trust model ensures that research-generated retained earnings are reinvested directly into building research capability across our hospital network.

During the year, trust funds supported workforce development, research leadership, education and training, conference participation, and research infrastructure. These investments help hospitals grow and sustain research activity, attract and retain skilled research staff, and increase opportunities for patients to participate in clinical research closer to home.

Through this reinvestment model, ACTT continues to generate lasting value for partner hospitals while strengthening Aotearoa New Zealand's clinical research ecosystem and supporting better health outcomes for the communities we serve.

Departmental breakdown of granting from designated reserves


Type	Designated Reserve
Personnel on trials	557,137
Transfers to trials	98,457
Conference	66,043
Equipment	17,685
Other	13,653
Database Support	4,560
Training	2,833
Publications	2,500
Total	**762,868**



Participant survey highlights

Rate your overall satisfaction with ACTT?	Would you recommend being involved in clinical research to others?	Rate the caring concern of our staff to you and helping you understand your condition?	Rate the friendliness of our staff to you and your whānau?	How would you rate your overall experience in being involved in clinical trial?
91% EXCELLENT	99% EXCELLENT	94% EXCELLENT	92% EXCELLENT	87% EXCELLENT

Main reasons for participating in a trial



Celebrating Research 2025

Celebrating Research 2025 at Middlemore Hospital brought together more than 100 attendees from across Counties Manukau Health and the wider research community, showcasing the breadth and impact of research being undertaken across the hospital.

The event celebrated excellence through a range of awards, recognising achievements in poster presentations and research leadership.

Award recipients:

GOLD POSTER AWARD
Dr Andrew Fox-Lewis

SILVER POSTER AWARD
Dr Kathleen Antony

BRONZE POSTER AWARD:
Robin Cronin

ANNAMARIE LOWNDES ASIAN HEALTH AWARD
Dr Shanthi Ameratunga

PEOPLE'S CHOICE WINNER
Robin Cronin

PEOPLE'S CHOICE RUNNER-UP
Cassandra Davis

COMMERCIAL RESEARCH AWARD
Dr Tien Huey Lim (Hepatology)

NON-COMMERCIAL RESEARCH AWARD
Dr Genevieve Walls
(Infectious Diseases)

EMERGING RESEARCHER AWARD
Dr Andrew Borrie (Cardiology)



From top, L-R:
Dr Andrew Fox-Lewis
Dr Kathleen Antony
Robin Cronin
Dr Shanthi Ameratunga
Dr Tien Huey Lim
Dr Genevieve Walls
Dr Andrew Borrie

The event also featured keynote speaker Professor David Murdoch, whose insights highlighted the importance of research, innovation, and collaboration in improving health outcomes. Celebrating Research 2025 was a successful showcase of achievement, partnership, and research excellence across our organisation.

Celebrating Research
DELIVERING THE FUTURE OF MEDICINE

Whakanui i te Rangahau
TUKU A MURI AKE NEI NGA RONGOA

We gratefully acknowledge the sponsorship of Fisher & Paykel Healthcare Foundation and Auckland Medical Research Foundation. The event was hosted by ACTT and supported by Health NZ | Te Whatu Ora Counties Manukau.

Participant story: a world-class experience

When Charles was referred to an ACTT clinical trial by his gastroenterologist, he had never considered taking part in clinical research before.



Charles

"I had no previous experience with clinical trials at all," he says. "I expected the process would be quite formal and complicated, with lots of appointments and procedures. I was actually surprised by how well organised and straightforward it was."

Charles joined the study for two reasons. Like many participants, he wanted to learn more about his own health condition. Just as importantly, he was motivated by the opportunity to help others.

"It was really about understanding my condition better but also helping other people. If medical research can develop new treatments and improve outcomes for someone else in the future, then it's a way of paying it forward."

Throughout his participation, Charles says the professionalism and support of the ACTT team stood out.

"The biggest surprise for me was how supportive and professional everyone was. They took the time to explain everything clearly, answer my questions and make sure I felt comfortable throughout the entire process."

Attending appointments at Middlemore Hospital was also easier than he anticipated.

"The facilities were fantastic. It was easy to find, parking was available, and the directions and maps provided were really helpful. Everything was designed to make the experience straightforward."

For Charles, however, what made the greatest difference was the people.

In a heartfelt email sent to acknowledge the care he received, he described Research Nurse Coordinator Mhairi McIntyre as "an absolute superstar."

"I am writing to express my deepest gratitude and appreciation for the incredible care, kindness, empathy and support she has shown me throughout my involvement in the trial," he wrote.

"Mhairi regularly called to check in on me, thoughtfully organised everything I needed and coordinated matters so efficiently and kindly. She has an incredible knowledge of the systems and processes and, whenever she didn't immediately know an answer, she went above and beyond to find it."

Reflecting on his overall experience, Charles says the human connection was what mattered most.

"I have a condition and somebody's listening. Somebody cares. Somebody genuinely wants to help."

He was particularly impressed by the team's commitment to finding answers and supporting participants every step of the way.

"Everybody I dealt with was knowledgeable. Each person had their specialty area, but if they didn't know the answer to a question, they took the time to go and find out. The overall experience was amazing."

Charles describes his experience with ACTT in two words: "World class."

As he looks back on his clinical trial journey, his message is one of gratitude.

"It's people who are passionate, who have a drive and who want to help others, that make the world of difference. I'm truly grateful. Thank you for the opportunity and for the care I received throughout the trial."

"My experience with the ACTT team has been world-class. I am incredibly grateful for the opportunity I have been given and for the exceptional service and care I have received."

Charles
Clinical Trial Participant

The person behind the participant

For Research Nurse Coordinator Mhairi McIntyre, one of the most important parts of her role is getting to know the person behind the participant.



Mhairi McIntyre

"Everyone has their own experiences and concerns," she says. "Sometimes it's as simple as listening and answering a question."

While clinical trials involve protocols, processes and careful coordination, Mhairi says her role is equally about supporting participants throughout their journey.

"My patients are not just a study number. They're people, and building that trust and connection is one of the most important parts of my role and what makes a clinical trial successful."

Mhairi was touched to receive a letter from participant Charles sharing his experience in a trial.

"The fact that Charles took the time to share his feedback meant a lot to me," she says. "It reminded me why I enjoy what I do and how grateful I am to be part of their trial journey and healthcare."

As a Research Nurse Coordinator, Mhairi is often a participant's main point of contact throughout a study. While much of the work happens behind the scenes, she says building relationships is a key part of helping participants feel comfortable and supported.

"There is a lot that happens behind the scenes to make a clinical trial run safely. We get to know our participants, and we are their main point of contact throughout their trial journey. The organisation and clinical knowledge is only one side of it. The other is the genuine care for the people taking part and making sure they feel safe, supported and heard."

Clinical trial participation can require a significant commitment, including regular visits, daily diaries and study medication. Mhairi hopes participants leave knowing their contribution matters.

"I really hope our participants feel supported and cared for throughout their journey, and know that the time and effort they give can truly make a difference for others in the future."

Mhairi McIntyre
Research Nurse Coordinator



ACTT Nurses on International Nurses Day

Staff Awards 2026

Our people are at the heart of everything we do. The ACTT Staff Awards recognise individuals whose dedication, professionalism, and commitment to our values help strengthen our organisation and advance our mission.

These awards celebrate those who consistently go above and beyond in supporting colleagues, delivering excellence, and contributing to a culture where people and research can thrive.



The ACTT Award

For consistently demonstrating the Company Core Values through their thoughts and actions.

Karen Carter
Director Clinical Operations



Certificate Of Excellence

For consistently demonstrating excellence through their efforts and interactions with other staff.

Louise Stubbing, PhD
Research Team Lead



Certificate Of Excellence

For consistently demonstrating excellence through their efforts and interactions with other staff.

Tanya Poppe, PhD
Regulatory Lead

Grant-funded research and highlights

ACTT plays a leading role in supporting grant-funded, investigator-led and collaborative group research across Aotearoa New Zealand. These studies address important unanswered clinical questions, contribute to improved patient care, inform health policy, and provide access to innovative treatments and interventions that may not otherwise be available.

Grant-funded research also supports the development of clinical research capability. Through participation in national and international collaborations, investigators contribute to scientific publications, build research leadership, and advance knowledge within their fields of expertise.

A key strength of the ACTT model is the complementary relationship between commercial and grant-funded research. Revenue generated through commercial studies is reinvested to strengthen departmental research capability and support future investigator-led and collaborative research projects. This sustainable model enables departments to expand research activity while building long-term capability within the health system.

ACTT's dedicated Grants team provides end-to-end support for clinical researchers at Middlemore and Whangārei Hospitals. This includes identifying and securing research funding, protocol development, budgeting, regulatory approvals, study management, participant recruitment, data management, and medical writing support. These services enable clinicians to undertake high-quality research alongside their clinical responsibilities and contribute to a strong culture of research excellence.

The Grants team is led by Nicola Jackson, PhD, Director - Grant Research, and is supported by Grant Portfolio Managers Sumudu Ranasinghe, PhD, Alexandra Mowday, PhD, and Alana Whitcombe, PhD, together with Clinical Research Coordinators Kate Wong She and Georgia Fowler.

During FY26, the Grants team supported **81 grant-funded clinical trials and research projects** across the ACTT network. Of these, **11 new studies** were activated across Respiratory, Cardiology, Renal, Haematology, Anaesthetics, Emergency Care, Intensive Care and Infectious Diseases.

Together, these studies are helping address some of Aotearoa New Zealand's most important health challenges while strengthening research capability, supporting clinician-led innovation, and expanding opportunities for patients to participate in high-quality clinical research.

Funding awarded:

Idiopathic Multicentric Castleman Disease study

The Idiopathic Multicentric Castleman disease (iMCD) study, led by Dr Samar Issa at Middlemore Hospital, has been awarded a Project Grant by Recordati valued at $19,000. iMCD is a rare multi-systemic condition which manifests with symptoms and signs of inflammation. There are often delays in diagnosing the condition due to poor recognition, varied presentation mimicking other systemic inflammatory disorders, and difficulty with obtaining and interpreting biopsy results. The aim of this national retrospective observational study is to describe, for the first time, the demographics, presentation, symptoms, diagnostic blood results, diagnostic timeframe, treatment, and outcomes for the iMCD population in Aotearoa New Zealand.

Study progress:

BALANCE+ A platform trial for gram negative bloodstream infections

The BALANCE+ trial, led by Dr Susan Morpeth, made significant progress during the year in improving antibiotic use in hospitalised adults with Gram-negative bloodstream infections. Following the award of Health Research Council funding in October 2025, the study successfully obtained ethics approval to conduct the trial in Aotearoa New Zealand. Recruitment commenced at Middlemore Hospital in December 2025 and has progressed strongly, with 61 participants enrolled by July 2026. Globally, BALANCE+ is now active across five countries (Canada (global lead site), Australia, Israel, Colombia, and Aotearoa New Zealand). The New Zealand BALANCE+ team are in the process of engaging with interested investigators and hospitals from around Aotearoa New Zealand to expand the trial, including Wellington, Christchurch, Tauranga, and North Shore, with locality approval underway at these sites. Alongside the main study, preparations are underway for an optional stool sampling sub-study, which will examine

changes in the faecal microbiome and the presence of antibiotic resistance genes before and after treatment, providing valuable insights into the broader impacts of antibiotic therapy. The BALANCE+ trial in Aotearoa New Zealand is funded by a 2025 Health Research Council Project Grant hosted by ACTT.

ROADMAP - Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform trial

The ROADMAP trial continues to gain strong momentum across Aotearoa New Zealand, with steady growth in recruitment and site activity. Globally, the trial now has 27 active sites, including three open and recruiting sites in Aotearoa New Zealand (Auckland, Middlemore, and Waitematā). Additional sites in Tauranga and Christchurch are expected to commence recruitment in the coming months. Recruitment to the trial is well underway. As of June 2026, 158 participants have been enrolled into the ROADMAP platform and 225 into the ROADMAP registry. Aotearoa New Zealand sites have made a significant contribution to these efforts, accounting for 22 platform enrolments (14% of the global total) and 55 registry enrolments (24% of the global total). The Aotearoa New Zealand ROADMAP team welcomes the support from investigator Dr John Mutu-Grigg (Ngāti Kahu, Te Rarawa), whose guidance will help Māori ROADMAP participants merge their hiahia (wishes), whakapono (beliefs) and māramatanga (understandings) on their prosthetic joint infection journey. The ROADMAP trial in Aotearoa New Zealand is funded by a 2024 Health Research Council Project Grant hosted by ACTT.

Reducing cardiac risk in outpatients with serious mental illness study

The Reducing cardiac risk in outpatients with serious mental illness study co-led by Dr Ian Soosay (Mental Health) and Dr Mayanna Lund (Cardiology) at Middlemore Hospital recruited its first participants in April 2026. This collaborative project between the Cardiology and Mental Health services, funded by the Freemasons Foundation, seeks to establish the feasibility of incorporating cardiovascular risk assessment into community mental health care. Patients with serious mental illnesses have a high risk of cardiovascular morbidity and mortality. By improving access to cardiovascular risk monitoring and management of risk factors, the project aims facilitate access for people in South Auckland to receive CVD risk assessments while also addressing challenges related to cost, staffing and interpreting results.

Research highlights

SNAP – *Staphylococcus aureus* Network Adaptive Platform trial

The SNAP trial delivered practice-changing evidence for the treatment of *Staphylococcus aureus* bloodstream infections, one of the world's most serious infectious diseases. Involving more than 1,600 participants across over 90 hospitals in eight countries, the study demonstrated that the antibiotics cefazolin (for methicillin-susceptible *S. aureus* (MSSA)) and penicillin (for penicillin-susceptible *S. aureus* (PSSA)) were at least as effective as, and likely superior to, (flu)cloxacillin in achieving 90-day survival, while also reducing the risk of acute kidney injury.

These findings support the use of cefazolin and penicillin as preferred treatment options and represent an important advance in improving outcomes and safety for patients. These results have been published in both The New England Journal of Medicine (PMID 42308484) and The Lancet (PMID 42309115), reinforcing their significance for clinical practice worldwide. The SNAP trial, led by Dr Genevieve Walls, is funded by a 2020 Health Research Council Project Grant hosted by ACTT.

Adolescent Bariatric Surgery Study

Outcomes of the Adolescent Bariatric Surgery study led by Dr Brandon Orr-Walker (Endocrinology) and Dr Richard Babor (General Surgery) at Middlemore Hospital have been published in the Diabetes Research and Clinical Practice journal (PMID 42105868).

The purpose of the Adolescent Bariatric Surgery study was to investigate the effect of intensive lifestyle intervention with or without bariatric (weight-reduction) surgery on the incidence of pre-diabetes, diabetes and related comorbidities in a cohort of high-risk morbidly obese adolescent participants.

The study shows that bariatric surgery combined with lifestyle intervention was associated with sustained reductions in albuminuria, suggesting a potential renoprotective effect in high-risk adolescents.The study findings are being used to inform a lifestyle programme to prepare adolescents for bariatric surgery. The Adolescent Bariatric Surgery study was co-funded by the Potter Masonic Trust and the Perpetual Guardian Carr and Davis Legacies and was delivered by Diabetes Foundation New Zealand with the support of ACTT.

PR-O-SNAP
Patient-reported perceptions, experiences and preferences around intravenous and oral antibiotics for the treatment of *Staphylococcus aureus* bacteraemia: a descriptive qualitative study.

Outcomes from a qualitative sub-study within the *Staphylococcus aureus* Network Adaptive Platform (SNAP) trial, led by medical student Loughlin McGrath, Dr Genevieve Walls (Infectious Diseases, Middlemore Hospital) and Dr Max Bloomfield (Te Whatu Ora Capital and Coast) have been published in Clinical Infectious Diseases (PMID 40988120). The study shows that choosing a route of antibiotic administration for treatment of severe infection is a nuanced decision which should incorporate not just a patient's clinical status, but also their preferences and personal context. This qualitative study, and its parent study, PR-O-SNAP, led by Dr Max Bloomfield and Dr Genevieve Walls, was commissioned by the Te Niwha Infectious Diseases Research Platform with funding from the MBIE Strategic Science Investment Fund.

Expanding department engagement in FY26:

Anaesthetics (Middlemore):

One new collaborative group trial (PROMPT O2) was activated and two trials were completed (SNaPP and TRIGS) in FY26 under the leadership of Dr Julian Dimech and Samantha Ryan (Specialty Clinical Nurse - Research and Quality Assurance). Outcomes for the SNaPP trial were published in The Lancet Respiratory Medicine (PMID 42263721). The study showed that in adults undergoing major surgery, sugammadex was associated with a small reduction in the incidence of postoperative lung complications compared with neostigmine.

Infectious Diseases (Middlemore)

Two new collaborative group trials (BALANCE+ and DAPTO-SNAP), led by Dr Susan Morpeth and Dr Genevieve Walls were activated in FY26. BALANCE+ in Aotearoa New Zealand is funded by a 2025 HRC Project Grant led by Dr Susan Morpeth.

Cardiology (Whangārei)

One new collaborative group trial (STUNNED Heart) led by Dr Daniel Chan was activated in FY26.

Renal (Whangārei)

One new collaborative group trial in Chronic Kidney Disease (EASiKIDNEY), led by Dr Adam Mullan was activated in FY26

Renal (Middlemore)

One new collaborative group trial in Chronic Kidney Disease (EASiKIDNEY), led by Dr Kalpa Jayanatha was activated in FY26

Haematology (Middlemore)

One new collaborative group trial in Relapsed/refractory Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (CAPTIVATE LTFU), led by Dr Sharon Jackson was activated in FY26.

One new investigator-initiated observation study in Idiopathic Multicentric Castleman disease (iMCD) led by Dr Samar Issa was activated in FY26. The iMCD study is funded by a research grant from Recordarti.

Grant-funded trials active in FY26

Middlemore	
Anaesthetics	4
Cardiology	2
Diabetes/Endocrinology	2
Emergency Department	12
Gastroenterology/Hepatology	2
Haematology	8
Infectious Diseases	6
Intensive Care	7
Mental Health	1
Neonatal	1
Ophthalmology	1
Paediatrics	20
Psychological Medicine	1
Renal	2
Respiratory	7
Stroke	1
Whangārei	
Cardiology	1
Paediatrics	1
Renal	2
Total	**81**

Commercial trials

ACTT delivers high-quality clinical trials through a hospital-based, nationally coordinated model that combines participant safety, regulatory excellence and operational performance.

Sponsors can be confident in receiving dependable, actionable results that support decision-making and regulatory approval. Participants can trust they are participating in, ethics approved research that may provide access to novel therapies and contribute to future medical advances. Speed is critical to successful trial delivery. ACTT works closely with sponsors, CROs and investigators to support rapid feasibility assessments, efficient contract negotiations, ethics and regulatory approvals, and timely participant recruitment. This integrated approach ensures studies activate quickly, maintain momentum and achieve key milestones on time.

Participant recruitment and retention are key strengths of ACTT's network. Through strong relationships with investigators, hospital departments and local communities, we consistently meet our recruitment targets across all therapeutic areas. We place a strong emphasis on participant experience, building trusted relationships that support engagement and study completion. This ongoing connection is reflected in the willingness of participants to take part in future research opportunities and our participant retention metrics (92% retention rate). Through trusted partnerships with sponsors and CROs, we remain committed to delivering on our recruitment goals and trial milestones.

Our strengths

- **International accreditation**

  Gold IAOCR accreditation, recognising ACTT as a clinical trial organisation of clinical excellence

- **Partnerships with leading investigators**

  Collaborations across over 28 hospital departments, providing access to experienced and emerging investigators across diverse therapeutic areas

- **Experienced research staff**

  Highly trained staff operating in accordance with ICH GCP guidelines and ACTT's Standard Operating Procedures

- **Rapid trial setup**
  - Fast feasibility turnaround – 11 days from feasibility received to completed
  - Dedicated Regulatory Lead to enable efficient Institutional Review Board (IRB) and Independent Ethics Committee (IEC) processes
  - Dedicated Start-Up Specialists
  - Timely budget and contract negotiations

- **Tailored recruitment strategies**

  Customised recruitment plans designed to meet our recruitment targets

- **Access to diverse populations**

  Strong partnerships across our hospital communities, Primary Care Organisations, local iwi and targeted digital outreach channels supporting inclusive and effective recruitment

- **Specialist pharmacy services**

  Compliant investigational product storage, preparation and management

- **Dedicated laboratory support**

  Timely and compliant onsite sample processing and shipping

- **Advanced Clinical Trial Management**

  Leading CTMS and feasibility management systems, paperless regulatory and participant files (eSource) and 24/7 remote monitoring access

Through trusted partnerships, efficient study activation and access to diverse participant populations, ACTT helps sponsors deliver world-class clinical trials while contributing to better health outcomes and a stronger future for healthcare in Aotearoa New Zealand.

Commercial trials - feasibilities

NEW FEASIBILITIES FOR CLINICAL TRIALS RECEIVED	FY26	270

Engagement by sponsors during FY26

AbbVie
Aethlon Medical
Agomab Therapeutics
AIRNA Corporation
AJNA BioSciences
Altimmune
Ambros Therapeutics
Apogee Therapeutics
Arovella Therapeutics
Arrowhead Pharmaceuticals
Astellas
AstraZeneca
Attovia Therapeutics
Avalyn Pharma Inc.
Averto Medical, Inc.,
BeOne (BeiGene)
Biohaven Therapeutics
Biomed Industries, Inc.
Boehringer Ingelheim
Botanic Health Care
Braveheart Bio, Inc.
Bristol-Myers Squibb (BMS)
Calliditas Therapeutics
Cardurion Pharmaceuticals
CellCentric Ltd.
Ceretas
Chiesi Farmaceutici
Chugai Pharmaceutical Co
Comanche Biopharma
Corvus Pharmaceuticals
CREATE Medicines
CRISPR Therapeutics
CytoAgents, Inc.
Dr. Falk Pharma
Edgewise Therapeutics
Editas Medicine
Eilean Therapeutics
EIT Pharma, Inc.
Eli Lilly
Enanta Pharmaceuticals
Enliven Therapeutics
Enveda
Eupraxia Pharmaceuticals
Evommune
Fisher & Paykel Healthcare
General Medicines
GlaxoSmithKline (GSK)
IDEAYA Biosciences
IntegerBio, Inc
ILTIMO
Immuneering Corporation
Immunovant, Inc.
Incyte
Ingenia Therapeutics
Inmagene
InnoCare Pharma Tech
Insmed
Jade Biosciences
Janssen-Cilag Pty Ltd
Jeyou
Kailera Therapeutics
Kaken Pharmaceutical Co., Ltd
Kali Therapeutics
Mammoth Biosciences
Mediar Therapeutics
MSD
Mirador Therapeutics
Mozart Therapeutics
Myopharm Limited
Nektar Therapeutics
Neuroscientific Biopharmaceuticals
Newave Pharmaceutical Inc.
Novartis
Novo Nordisk
NS Pharma
Nurix Therapeutics
Nyrada Inc
Odyssey Therapeutics
OliX Pharmaceuticals
Otsuka Pharmaceutical
Pahr Therapeutics
Pfizer
Pinnacle Medicines
Praeventix, Inc
Prana Therapies
Prime Medicine Inc.
Primmune Therapeutics
Priovant Therapeutics
PureTech
QBiotics
Quantech Group
RAGE Biotech Pty Ltd
Roche
Scribe Therapeutics
Septerna, Inc.
Seyltx
Shanghai Junshi Biosciences
Shattuck Labs
Sirius Therapeutics, Inc.
Sironax USA
Strand Therapeutics
Suzhou Suncadia Biopharmaceuticles
SynAct Pharma ApS
Takeda Pharmaceutical Company Limited
Tectonic Therapeutic
Therini Bio
Tortugas Neuroscience
TRex Bio
Uniquity Bio, Inc.
United Therapeutics
Vast Therapeutics
VectivBioAG
Verona Pharma
Xencor
XW Pharma
Zai Lab
Zealand Pharma


CROs

Alimentiv
APT Clinical Trials
Avance Clinical
Biogenesis
Bubble Clinical Research Services
CareAccess
ClinChoice Inc.
Complete Phase CRO
Credevo
CTI
Fortrea
HiRO
ICON
Indero
IQVIA
Medpace
Mobius Medical
Novotech
PAREXEL International
PPD
Propharma
PSI-CRO
QPS
ReSQ Clinical Research
SAPRO
Southern Star Research
Syneos Health
Tigermed
Victorian Heart Institute
Worldwide Clinical Trials (WCT)

Commercial trials by the numbers


FY26 commercial trials by study phase / type

- Device 2%
- Phase I 6%
- Phase I/II 3%
- Phase II 16%
- Phase III 71%
- LTE/OLE 2%



FY25 commercial trials by study phase / type

- Device 4%
- Phase I 8%
- Phase II 12%
- Phase III 76%



Commercial trials by recruiting departments in FY26


Department	Trials	Participants
ACTT Middlemore		
Cardiology	5	56
Dermatology	2	6
Diabetes	1	9
Endocrinology	8	87
Gastroenterology	5	21
Haematology	17	42
Hepatology	4	16
Renal	3	21
Respiratory	8	34
Rheumatology	7	20
Stroke	1	5
ACTT Whangārei		
Cardiology	3	52
Oncology	1	5
Renal	1	17
Total	**67**	**399**

FY26 ACTT commercial trial overview

Active commercial trials



Commercial trial protocols activated



Areas of research - activity by department in FY26

Many of these trials provide participants with access to treatments that are otherwise not available in Aotearoa New Zealand or not available for the condition under investigation.

Anaesthetics - Middlemore

COMMERCIAL TRIALS	1
GRANT-FUNDED TRIALS	4

Therapeutic areas

- Post-operative pain
- Post-operative infection
- Perioperative Medicine: Oxygen Therapy
- Post-operative pulmonary complications

Investigators

Dr Julian Dimech
Dr Heather Murray
Dr Matthew Jenkins

Support Staff

Samantha Ryan (Anaesthetics Research Nurse)

Cardiology - Middlemore

COMMERCIAL TRIALS	9
GRANT-FUNDED TRIALS	2

Therapeutic areas

- Takotsubo Syndrome
- Acute Coronary Syndrome
- Atrial Fibrillation
- Cardiovascular Disease
- Transthyretin Amyloid Cardiomyopathy

Investigators

Dr Mayanna Lund
Dr Jen Li Looi
Dr Andrew Borrie
Dr Douglas Scott
Dr Jayden Batey
Dr Tim Sutton
Dr Danting Wei
Dr Krishna Gupta
Dr Stephen Li
Dr Uddaka Wijesinghe
Dr Sae Boel Ahn

Support Staff

Jill Gilmore

Cardiology - Whangārei

COMMERCIAL TRIALS	4
GRANT-FUNDED TRIALS	1

Therapeutic areas

- Acute Myocardial Infarction
- Acute Coronary Syndrome
- Cardiovascular Disease

Investigators

Dr Daniel Chan
Dr Marcus Lee

Dermatology - Middlemore

COMMERCIAL TRIALS	2

Therapeutic areas

- Atopic Dermatitis
- Alopecia Areata

Investigators

Dr Cheng Huang
Dr Sabrina Sapsford
Dr Amritpreet Singh
Dr Paul Jarrett

Diabetes/Endocrinology - Middlemore

COMMERCIAL TRIALS	14
GRANT-FUNDED TRIALS	2

Therapeutic areas

- Diabetic Kidney Disease
- Bariatric Surgery
- Cardiometabolic Disease
- Cardiovascular Disease
- Dyslipidaemia
- Grave's Disease
- Hyperlipidaemia
- Obesity
- Type I Diabetes
- Type II Diabetes

Investigators

Dr John Baker
Dr Brandon Orr-Walker

Emergency Department - Middlemore

COMMERCIAL TRIALS	1
GRANT-FUNDED TRIALS	12

Therapeutic areas

- ED Adverse Events
- Septic Shock
- Paediatric Neck Injuries
- Sepsis
- Fever and Pain
- Febrile Convulsion
- Traumatic Brain Injury
- Traumatic Haemorrhage
- Asthma/Wheeze
- Concussion
- Resuscitation

Investigators

Dr Eunicia Tan
Dr Christopher Lash
Dr Andew Brainard
Dr Scott Gutovitz

Support Staff

Georgia Doyle (ED Research Nurse)
Alex Grigg (ED Research Nurse)
Sandra Neva (ED Research Nurse)
Helen Barrett (ED Research Nurse)
Abbie Hamilton (ED Research Nurse)

Gastroenterology & Hepatology - Middlemore

COMMERCIAL TRIALS	18
GRANT-FUNDED TRIALS	2

Therapeutic areas

- Pancreatic Cancer
- Oesophageal adenocarcinoma
- Crohn's Disease
- Eosinophilic Esophagitis
- Gastroparesis
- Ulcerative Colitis
- Hepatitis B
- Liver Fibrosis
- Metabolic Dysfunction-Associated Steatohepatitis
- Metabolic Dysfunction Associated Steatotic Liver Disease

Investigators

Dr Derek Luo
Dr Anurag Sekra
Dr Tien Huey Lim
Dr Sriharan Selvaratnam
Dr Adele Melton
Dr Emma Robinson
Dr Mirthe Van der Valk
Dr Hayneil Solanki
Dr Seong Shin
Dr Dali Fan

General Medicine - Middlemore

COMMERCIAL TRIALS	1

Therapeutic area

- Rapamycin

Investigator

Dr Joanna Wojciechowska

Hepatology - Whangārei

COMMERCIAL TRIALS	1

Therapeutic area

- Metabolic Dysfunction Associated Steatotic Liver Disease

Investigators

Dr Byron Theron
Dr Paras Garg

Haematology - Middlemore

COMMERCIAL TRIALS	27
GRANT-FUNDED TRIALS	8

Therapeutic areas

- Chronic Myeloid Leukaemia
- Idiopathic multicentre Castleman disease
- Relapsed/refractory Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma
- Post-transplant lymphoproliferative disorder
- Acute Myeloid Leukaemia
- B-Cell Lymphoma
- Essential Thrombocythemia
- Follicular Lymphoma
- Myelodysplastic Syndrome
- Myelofibrosis
- Non-Hodgkin's Lymphoma
- FXa direct oral anticoagulant reversal agent

Investigators

Dr Sharon Jackson
Dr Gordon Royle
Dr James Liang
Dr Samar Issa
Dr Kirsty Marshall

Infectious Diseases - Middlemore

COMMERCIAL TRIALS	1
GRANT-FUNDED TRIALS	6

Therapeutic areas

- COVID-19
- *Staphylococcus aureus* bacteraemia
- Legionnaires' Disease
- Prosthetic Joint Infection
- Gram Negative Bloodstream Infections
- Influenza A

Investigators

Dr Susan Morpeth
Dr Genevieve Walls
Dr Michael Borrie
Dr Natasha Pool
Dr Christopher Luey
Dr Trent Herdman
Dr Christopher Hopkins
Dr Tim Cutfield

Support Staff

Rima Song
ED Research Nurses
Kidz First Research Nurses
Elizabeth Bryce

Intensive Care Medicine - Middlemore

COMMERCIAL TRIALS	1
GRANT-FUNDED TRIALS	7

Therapeutic areas

- Community-acquired pneumonia
- Mechanically ventilated patients following trauma
- Sedation
- Critical Illness
- Cardiac Arrest and Resuscitation
- Metabolic Acidosis
- Acute hypoxaemic respiratory failure

Investigators

Dr Tony Williams
Dr Michael Borrie

Support Staff

Rima Song (ICU Research Nurse)
Tina Mwembani (ICU Research Nurse)
Vivian Lai (ICU Research Nurse)

Mental Health - Middlemore

GRANT-FUNDED TRIALS	1

Therapeutic area

Cardiac Risk

Investigators

Dr Ian Soosay
Dr Mayanna Lund (Cardiology)

Support Staff

Debra Gerrard

Neonatal - Middlemore

COMMERCIAL TRIALS	1
GRANT-FUNDED TRIALS	1

Therapeutic areas

- CPAP
- RSV

Investigator

Dr Michael Meyer

Oncology - Whangārei

COMMERCIAL TRIALS	1

Therapeutic area

- Breast cancer

Investigator

Dr Edmond Ang

Ophthalmology - Middlemore

GRANT-FUNDED TRIALS	1

Therapeutic area

- Keratoconus

Investigator

Dr Rasha Al-Taie

Paediatrics - Middlemore

GRANT-FUNDED TRIALS	20

Therapeutic areas

- Preschool wheeze
- Child Health Equity
- Recurrent Respiratory-Related Acute Lower Respiratory Infections
- Māori Child Health
- Childhood Respiratory Illness
- *Staphylococcus aureus* bacteraemia
- Group A Streptococcus infection
- Implicit Bias
- Acute Rheumatic Fever
- Sydenham's Chorea
- Physiotherapy
- Asthma/Wheeze
- Influenza

Investigators

Dr Adrian Trenholme
Dr Catherine Byrnes
Dr Rachel Webb
Dr Rebecca Alekzander
Dr Cameron Burton
Dr Adam Dennison
Dr Laura Rensford

Support Staff

Shirley Lawrence (Kidz First Research Nurse)
Beula Vincent (Kidz First Research Nurse)
Laarni Tundag (Kidz First Research Nurse)
Gail Spence (Kidz First Research Nurse)
Maricar Maminta (Kidz First Research Nurse)
Rachel Lee (Kidz First Research Nurse)

Paediatrics - Whangārei

GRANT-FUNDED TRIALS	1

Therapeutic area

- Sydenham's Chorea

Investigator

Dr Ailsa Tuck

Support Staff

Kezia Schroyen

Psychological Medicine - Middlemore

GRANT-FUNDED TRIALS	1

Therapeutic area

- Delirium

Investigator

Dr John Hopkins

Support Staff

PyiPyi Phyo

Renal - Middlemore

COMMERCIAL TRIALS	4
GRANT-FUNDED TRIALS	2

Therapeutic areas

- Chronic Kidney Disease
- Cardiovascular Disease
- IgA Nephropathy

Investigator

Dr Kalpa Jayanatha
Dr Joanna Dunlop
Dr Youngmin Goo

Support Staff

Jennifer Urquico

Renal - Whangārei

COMMERCIAL TRIALS	1
GRANT-FUNDED TRIALS	2

Therapeutic areas

- Chronic Kidney Disease
- Polycystic Kidney Disease

Investigator

Dr Adam Mullan
Dr Jason Lee

Support Staff

Rudi Kok

Respiratory - Middlemore

COMMERCIAL TRIALS	17
GRANT-FUNDED TRIALS	7

Therapeutic areas

- Bronchiectasis
- Asthma
- Lung Cancer
- Pneumothorax
- Alpha-1 Anti-trypsin Deficiency
- COPD
- Idiopathic Pulmonary Fibrosis
- Non-cystic fibrosis bronchiectasis
- Pulmonary Hypertension
- Respiratory Failure

Investigators

Dr Stuart Jones
Dr Conroy Wong
Dr Elaine Yap
Dr Paul Dawkins
Dr Conor O'Dochartaigh
Dr Jeffrey Garrett
Dr Robert Lewis
Dr William Good
Dr Jeong Oh
Dr Leon Chang
Dr Charlotte Chen
Dr Muhammad Babar Maqbool
Dr Grace Choy



Nicholas Kan, Medical Laboratory Technician

Rheumatology - Middlemore

COMMERCIAL TRIALS	17

Therapeutic areas

- Ankylosing Spondylitis
- Diffuse Cutaneous Systemic Sclerosis
- Gout
- Lupus
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Sjogren's Syndrome

Investigators

Dr Sunil Kumar
Dr Mark Sapsford
Dr Linda (Lu-Yin) Yen
Dr Connor Skipworth
Dr Rathan Nagarajah

Stroke - Middlemore

COMMERCIAL TRIALS	1
GRANT-FUNDED TRIALS	1

Therapeutic areas

- Stroke prevention
- Stroke treatment

Investigators

Dr Karim Mahawish
Dr Arindam Kar

Support Staff

Stroke Clinical Nurse Specialists

Vaccinology - Middlemore

COMMERCIAL TRIALS	3

Therapeutic areas

- COVID-19
- RSV
- Urinary tract infections

Investigators

Dr Aritra Ray
Dr John Baker
Dr Ian Rosen

Reserve balances

Designated + Restricted Reserve	Opening balance	Granting	% Of opening	Closing balance
MIDDLEMORE HOSPITAL				
Cardiology Research Fund	1,551,187	28,592	2%	1,583,565
Dermatology Research Fund	71,102	9,753	14%	71,284
Diabetes Fund	63,169	34,043	54%	152,162
Emergency Care Clinical Research & Education	20,503	10,616	52%	195,204
Gastro Research Fund (including Hepatology)	659,194	107	0%	697,123
Haematology Research & Special Purposes Fund	1,489,182	111,500	7%	1,426,049
Home Health Fund	31,650	- 0		31,650
Intensive Care Unit Fund	739,794	70,973	10%	698,112
Infectious Diseases Research and Education Fund	168,603	1,193	1%	205,760
Paediatrics Kidz First Research Development Fund	799,743	135,784	17%	829,840
Microbiology Fund	17,924	- 0		17,924
Neonatal Research	107,407	72,046	67%	112,886
Oropharyngeal Department Fund	8,742	- 0		8,742
Middlemore Hand and Upper Limb Research Fund	117,950	62,142	53%	115,517
Radiology Research Fund	10,343	- 0		10,343
Renal Fund	70,496	9,793	14%	76,446
Respiratory Research Fund	577,862	155,599	27%	530,213
Rheumatology Research Fund	572,928	12,724	2%	618,576
Womens Health Fund	5,657	- 0		5,657
CIU Education Fund	- 0	- 0		- 0
Anaesthetics	52,923	605	1%	66,022
Orthopaedics	32,147	- 0		32,208
General Surgery	2,151	- 0		275,657
Ophthalmology	-249	- 250	100%	1
Plastics	50,493	45,813	91%	55,425
Midwifery	1,300	- 0		1,300
Mental Health	31,938	- 0		31,938
Oncology	- 0	- 0		- 0
ARHOP	24,220	- 0		29,729
Spinal Unit	24,428	1,727	7%	22,795
Acute Allied Health	5,025	- 0		5,025
Stroke Outcomes Fund	48,992	- 0		48,992
AT&R Research Fund	289	- 0		289
WHANGĀREI HOSPITAL				
Cardiology Research Fund	10,459	108	1%	25,370
Emergency Department Research Fund	1,484	-	-	1,484
Renal Fund	- 99	-	-	8,701
General Surgery	24,330	-	-	34,173
Oncology	2,180	-	-	4,984
	7,395,447	**762,868**	**10%**	**8,031,145**

Publications FY26

ARISE FLUIDS Investigators, t. A. C. T. G., and the ACEM Clinical Trials Network, Peake, S. L., Macdonald, S. P. J., Howe, B. D., Milford, E., Jones, P., Arendts, G., Bailey, M., Burcham, J., Delaney, A., Egerton-Warburton, D., Fatovich, D., Fraser, J. F., Higgins, A. M., Keijzers, G., Udy, A. A., Williams, P., Young, P. J., & Bellomo, R. . (2026). **Vasopressors or Fluids in Early Septic Shock**. *New England Journal of Medicine*, 0(0). https://doi.org/doi:10.1056/NEJMoa2516225

Balamuth, F., Weiss, S. L., Long, E., Thompson, G. C., Artis, A. S., Campos, A. B., Borland, M. L., Dalziel, S. R., Yock-Corrales, A., Singh, R., Williams, A., Mickiewicz, B., Hickey, C. P., Fitzgerald, J. C., Laskin, B. L., Hickey, R. W., Eckerle, M., Alqurashi, W., Alpern, E., . . . Networks, P. (2026). **Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock**. *N Engl J Med*. https://doi.org/10.1056/NEJMoa2601969

Daneman, N., Johnstone, J., Lee, T. C., MacFadden, D. R., McDonald, E. G., **Morpeth, S. C.**, Ong, S. W. X., Paterson, D. L., Pinto, R. L., Rishu, A., Rogers, B. A., Yahav, D., Coburn, B., Daley, P., Das, P., Fiest, K., Findlater, A., Fralick, M., George, M., . . . the Canadian Critical Care Trials, G. (2025). **Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE**. *BMJ Open*, 15(12), e101588. https://doi.org/10.1136/bmjopen-2025-101588

Das, S., Bloomfield, F. H., **Alexander, T.**, Jiang, Y., Gamble, G., Lin, L., & Harding, J. E. (2026). **Feeding Infants Born Moderate-to-Late Preterm: 2-Year Follow-Up of the DIAMOND Randomized Trial**. *J Pediatr*, 114989. https://doi.org/10.1016/j.jpeds.2026.114989

Das, S., Bloomfield, F. H., **Alexander, T.**, Jiang, Y., Gamble, G., Lin, L., & Harding, J. E. (2026). **Two-Year Follow-Up of the Different Approaches to Feeding Infants Born Moderate-to-Late Preterm: Determinants of Feed Intolerance, Body Composition, and Development (DIAMOND) Randomized Trial**. *J Pediatr, 292*, 114989. https://doi.org/10.1016/j.jpeds.2026.114989

Derde, L., Gordon, A. C., Mouncey, P. R., Al-Beidh, F., Rowan, K. M., Nichol, A. D., Arabi, Y. M., Annane, D., Beane, A., Beasley, R., Bonten, M. J. M., Bradbury, C. A., Brunkhorst, F. M., Buzgau, A., Buxton, M., Cheng, A. C., Cooper, N., Cove, M., Cremer, O. L., . . . van de Veerdonk, F. L. (2025). **Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial**. *Thorax, 80*(8), 530-539. https://doi.org/10.1136/thorax-2024-222488

Fernandez-Bustamante, A., & Eikermann, M. (2026). **Sugammadex versus neostigmine and postoperative pulmonary complications: a word of caution**. *Lancet Respir Med*. https://doi.org/10.1016/S2213-2600(26)00185-2

Furie, R. A., Dall'Era, M., Vital, E. M., Garg, J. P., Irazoque Palazuelos, F., Zuta Santillan, A. E., Ravelo-Hernandez, J., Santiago, M. B., Zazueta Montiel, B., Botha, S., Leszczynski, P., de Souza, V. A., Sicsik, S. A., Bellatin, L., Naidoo, A., Amoura, Z., D'Agostino, M. A., **Kumar, S.**, Workeneh, B., . . . Investigators, A. T. (2026). **Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus**. *N Engl J Med, 395*(3), 243-254. https://doi.org/10.1056/NEJMoa2516150

Gane, E., Wong, G. L., Currie, S., Luber, A., MacDonald, P., Bonhomme, M., & **Lim, T. H.** (2026). **VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial**. *Lancet Microbe*, 101448. https://doi.org/10.1016/j.lanmic.2026.101448

Gill, H., Palandri, F., Ross, D. M., Göthert, J. R., Cochrane, T., Larsen, S. R., Halpern, A. B., Shortt, J., Rossetti, J. M., **Liang, J.**, Marchetti, M., Wilson, A. J., Innes, A. J., Hanna, M., Vianelli, N., Stevenson, W. S., Vannucchi, A. M., Kleppe, M., Flynn, J., . . . Rienhoff, H. Y., Jr. (2026). **Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia**. *Blood Advances, 10*(10), 3494-3504. https://doi.org/10.1182/bloodadvances.2025017575

Goodman, A. L., Easom, N., Bielopolski, D., Sutherland, R. K., Marks, M., Hensgens, M. P. M., Bonten, M., Bostock, J., **Walls, G.**, Lye, D., Boyles, T., Yahav, D., Cheng, M. P., Legg, A., Paul, M., Lescure, F. X., Lee, T. C., Tong, S. Y. C., & Davis, J. S. (2026). **A review of the randomized clinical trial results from the *Staphylococcus aureus* network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa**. *J Antimicrob Chemother, 81*(8). https://doi.org/10.1093/jac/dkag215

Hashmi, M., Haniffa, R., Jayakumar, D., Beane, A., Lorenzi, E., Berry, L. R., Nasir Khoso, M., Ain Khan, Q., Kumar, A., Altaf Kidwai, A., Hills, T. E., Annane, D., Aryal, D., Au, C., Baillie, K., Beasley, R., Best-Lane, J., Bonten, M., Bradbury, C. A., . . . and the Randomized, E. M. A. P. T. f. C.-A. P. I. (2026). **Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)**. *Crit Care Med*. https://doi.org/10.1097/CCM.0000000000007134

Hou, J., Lim, S. G., Buti, M., Yuen, M. F., Gane, E., Lampertico, P., Terrault, N., Nguyen, H., Yim, H. J., Xie, Q., Lin, J., Qiu, Y., Jeng, W. J., Heo, J., Peng, C. Y., Chen, C. H., Chuang, W. L., Xie, Y., Hlebowicz, M., . . . Group, B. W. S. (2026). **Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection**. *N Engl J Med*. https://doi.org/10.1056/NEJMoa2515131

Investigators, R.-C., Bradbury, C. A., McVerry, B. J., Lawler, P. R., Angus, D. C., Annane, D., Arabi, Y. M., Aryal, D., Au, C., Beane, A., Berry, S. M., Berry, L. R., Best-Lane, J., Bihari, S., Bonten, M., Brunkhorst, F., Burrell, A., Buxton, M., Carrier, M., . . . Zarychanski, R. (2026). **Intermediate Dose Heparin Thromboprophylaxis among Critically Ill Patients with COVID-19: A Randomised Clinical Trial**. *J Thromb Haemost*. https://doi.org/10.1016/j.jtha.2026.03.006

Kerr, A., Harwood, M., Grey, C., Mehta, S., Stone, T., Lee, M., Wells, S., Jackson, R., & Poppe, K. (2025). **Half a century of declining acute coronary syndrome incidence is ending and ethnic inequity is rising: ANZACS-QI 88**. *N Z Med J, 138*(1627), 42-54. https://doi.org/10.26635/6965.7132

Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., **Baker, J.**, Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2025). **Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3**. *N Engl J Med, 393*(21), 2119-2130. https://doi.org/10.1056/NEJMoa2511778

Leslie, K., Braat, S., Darvall, J. N., Peyton, P. J., Devlin, N., Myles, P. S., Corcoran, T. B., Short, T. G., Chan, M. T. V., Olesnicky, B. L., Tran-Duy, A., Maxwell-Wright, H., Schultz-Ferguson, C., Sidiropoulos, S., & Story, D. A. (2026). **Sugammadex, neostigmine, and postoperative pulmonary complications: protocol of the SNaPP multicentre randomised controlled trial**. *BJA Open, 17*, 100531. https://doi.org/10.1016/j.bjao.2026.100531

Long, E., Selman, C., Borland, M. L., George, S., Jani, S., **Tan, E.**, Phillips, N., Kochar, A., Craig, S., Lithgow, A., Whyte, E., Gelbart, B., McNab, S., Dalziel, S., Balamuth, F., Weiss, S. L., Kuppermann, N., Williams, A., Babl, F. E., & Paediatric Research in Emergency Departments International Collaborative, n. (2026). **IV bolus, maintenance and medication carrier fluid in children with community-acquired sepsis: a multicentre cohort study**. *Arch Dis Child*. https://doi.org/10.1136/archdischild-2025-330189

Luo, A., Oakley, A., Han, D. Y., & **Jarrett, P.** (2025). **Health Equity and Secukinumab for Severe Psoriasis in New Zealand**. *Australasian Journal of Dermatology, 66*(6), 321-375. https://doi.org/https://doi.org/10.1111/ajd.14539

Mahawish, K. M., Krishnamurthi, R., Davis, A., Zagreanu, C., Zeng, I., White, H. D., & Feigin, V. (2026). **Declining Incidence of Atrial Fibrillation–Associated Ischemic Stroke in Auckland, New Zealand** (2012 Versus 2021). *Journal of the American Heart Association, 15*(5), e045260. https://doi.org/doi:10.1161/JAHA.125.045260

Mathy, J. A., Patel, A. U. C., Buan, J. S., Ustin, J., & Martin, R. (2025). **Clinical Evaluation of a Novel, Chemically-Generated, Single-Use Negative Pressure Wound Therapy System for the Management of Closed Surgical Incisions**. *Cureus, 17*(6), e86148. https://doi.org/10.7759/cureus.86148

McDonald, E. G., Cheng, M. P., Davis, J. S., Goodman, A. L., Lawler, P. R., Marsh, J., Mertz, D., Paul, M., Rodriguez-Bano, J., Siegal, D. M., Tong, S. Y., **Walls, G.**, Lee, T. C., & Committee, S. G. T. S. (2025). **Is there a role for anticoagulation with dabigatran in *S. aureus* bacteremia? Protocol for the adjunctive treatment domain of the *Staphylococcus aureus* Network Adaptive Platform (SNAP) randomised controlled trial**. *BMJ Open, 15*(12), e107493. https://doi.org/10.1136/bmjopen-2025-107493

McQuilten, Z., O'Sullivan, M. V. N., Purcell, D., Edler, P., Meagher, N., Alcorn, K., Bowen, A., Daly, J., Foo, H., Goulding, S., Gosbell, I., Hammond, N., Hills, T., Hoad, V., Jha, V., Lim, L. L., McPhee, G., Molton, J., **Morpeth, S.**, . . . Denholm, J. T. (2025). **Convalescent plasma in hospitalised patients with COVID-19**. *Intern Med J, 55*(12), 2024-2032. https://doi.org/10.1111/imj.70253

Mudrik-Zohar, H., Cutfield, T., **Morpeth, S.**, Hills, T., Duffy, E., Edwards, L. J., Cheng, A. C., & Tong, S. Y. C. (2026). **Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population**. *Med J Aust, 224*(7), e70241. https://doi.org/10.5694/mja2.70241

Perera, K., Baker, J., Smallman, K., Pickering, K., Harry, P., Anderson, D., **Orr-Walker, B.**, Babor, R., & **Simmons, D**. (2026). **Albuminuria trajectories following intensive lifestyle intervention with or without bariatric surgery in adolescents with and at risk of type 2 diabetes**. *Diabetes Research and Clinical Practice, 237*. https://doi.org/10.1016/j.diabres.2026.113296

Plint, A. C., Heath, A., Rowe, T., Vogel, K. I., Wills-Ibarra, N., O'Brien, S., Borland, M. L., Johnson, D. W., Zorc, J. J., Pechlivanoglou, P., Schuh, S., Rao, M., Bonisch, M., Craig, S. S., Gouin, S., Kochar, A., Thompson, G. C., **Lash, C.**, Wallace, A., . . . Dalziel, S. R. (2025). **A randomised controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitis: the Bronchiolitis in Infants Placebo versus Epinephrine and Dexamethasone (BIPED) study protocol**. *ERJ Open Res, 11*(5). https://doi.org/10.1183/23120541.01298-2024

Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia, I., Bradbury, C. A., McVerry, B. J., Lawler, P. R., Angus, D. C., Annane, D., Arabi, Y. M., Aryal, D., Au, C., Beane, A., Berry, S. M., Berry, L. R., Best-Lane, J., Bihari, S., Bonten, M., Brunkhorst, F., Burrell, A., Buxton, M., Carrier, M., . . . Zarychanski, R. (2026). **Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial**. *J Thromb Haemost, 24*(7), 2492-2505. https://doi.org/10.1016/j.jtha.2026.03.006

Staphylococcus aureus Network Adaptive Platform Trial, G., Lee, T. C., Barina, L. A., **Walls, G.**, Goodman, A. L., Yahav, D., Cheng, M. P., Bonten, M., Bowen, A. C., Boyles, T., Daneman, N., Ekkelenkamp, M. B., Ghanem-Zoubi, N., Hensgens, M. P. M., Jager, N. G. L., Kaasch, A. J., Kouijzer, I. J. E., Lewis, R. J., Lumley, T., . . . Tong, S. Y. C. (2026). **Cefazolin for Methicillin-Susceptible *Staphylococcus aureus* Bacteremia**. *N Engl J Med, 394*(23), 2329-2339. https://doi.org/10.1056/NEJMoa2506905

Staphylococcus aureus Network Adaptive Platform Trial, G. (2026). **Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible *Staphylococcus aureus* bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial**. *Lancet, 408*(10550), 141-152. https://doi.org/10.1016/S0140-6736(26)00761-0

Tan, E., McKinlay, C. J. D., Riley, J., Rao, M., Mravicich, L., **Lawrence, S.**, Eathorne, A., Braithwaite, I., Semprini, A., Okesene-Gafa, K., Sheridan, N., Hoare, K., Grant, C., Johnson, D., Weatherall, M., Beasley, R., & Dalziel, S. R. (2026). **Paracetamol versus ibuprofen as required for fever or pain in the first year of life and the risk of eczema and bronchiolitis at age 1 year in New Zealand (PIPPA Tamariki): a multicentre, open-label, parallel-group, superiority, randomised controlled trial**. *Lancet Child Adolesc Health*. https://doi.org/10.1016/S2352-4642(25)00341-4

Verheye, S., Ferdinande, B., Bennett, J., Staico, R., El-Jack, S., Tonino, P. A. L., Abizaid, A., Buysschaert, I., **Scott, D.**, Menon, M., Wilkins, G., McClean, D., Kovarnik, T., Christians, U., Neylon, A., Mehmedbegovic, Z., Smits, P. C., Morice, M. C., Webster, M., & Investigators, D. E. B. P. R. (2025). **Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus**. *Catheter Cardiovasc Interv*. https://doi.org/10.1002/ccd.70106

Wagener, J., Shan, U., Anderson, W. F., Mason, I. T. T., May, B. C. H., & **Locke, M. B.** (2025). **Pilot Study: Prospective, First-in-human Clinical Evaluation of a Novel Tissue Apposition Device (ENIVO) Following Simple Unilateral Mastectomy**. *Plast Reconstr Surg Glob Open, 13*(8), e7027. https://doi.org/10.1097/GOX.0000000000007027

Walls, G., McGrath, L., Herdman, M. T., Campbell, A. J., Cheng, M. P., Marks, M., Oever, J. T., Sahng, E., Yahav, D., Tong, S. Y. C., Goodman, A. L., Lim, A. G., Bloomfield, M., & *Staphylococcus aureus* Network Adaptive Platform Trial Early Oral Switch Domain Specific Working, G. (2025). **Patient-reported perceptions, experiences and preferences around intravenous and oral antibiotics for the treatment of *Staphylococcus aureus* bacteremia: a descriptive qualitative study**. *Clin Infect Dis*. https://doi.org/10.1093/cid/ciaf522

Watts, G. F., Scott, R., Sullivan, D., **Baker, J.**, Clifton, P., Hamilton, J., Given, B., Melquist, S., Zhou, R., Gaudet, D., Goldberg, I. J., Knowles, J. W., Leeper, N. J., Hegele, R. A., & Ballantyne, C. M. (2026). **Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial**. *Nat Med, 32*(4), 1432-1443. https://doi.org/10.1038/s41591-026-04307-8

Wu, L. H., Pakkiri, L. S., Tromp, J., Lim, P. L., Liu, X., Chan, S. P., Yang, J., Samant, R., Dong, J., Goh, E., Lee, J., Ling, L. H., Gamble, G. D., Sim, D., Leong, K. T. G., Yeo, P. S. D., Ong, H. Y., Jaufeerally, F., Ng, T. P., . . . **Lund, M.**, . . . Drum, C. L. (2026). **Differential metabolomic prediction of outcomes in HFpEF and HFrEF: a prospective international multi-ethnic cohort study**. *Cardiovasc Res*. https://doi.org/10.1093/cvr/cvag090

Sponsors and CROs

SPONSORS:



CROs:



Aotearoa Clinical Trials

MIDDLEMORE HOSPITAL

Phone: 0800 ENROLL (0800 367 655)

Email: info@aotearoatrials.nz

Physical address:
Esme Green, Middlemore Hospital,
100 Hospital Road, Otahuhu,
Auckland 2025

WHANGĀREI HOSPITAL

Phone: 09 4304101

Email: info@aotearoatrials.nz

Physical Address:
Maunu House, Maunu Road,
Horahora, Whangārei 0148

www.aotearoatrials.nz